Biocon’s wholly owned subsidiary--- Biocon Biologics India (BBIL) has received the subscription money aggregating to Rs 536.25 crore from Activ Pine LLP (an affiliate of True North Fund VI LLP). Consequently, the Board of BBIL has approved the allotment of 50,25,463 equity shares of Rs 10 each at a price of Rs 1,067.07 per equity share (including a premium of Rs. 1,057.07 per equity share) to Activ Pine LLP. Earlier, Biocon, BBIL and Activ Pine LLP have executed a share subscription agreement and a shareholder agreement.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
